2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.08 Furmonertinib as First-Line Therapy for Chinese Patients with EGFR Mutation-positive NSCLC: A Real-World Study

EP.12A.08 Furmonertinib as First-Line Therapy for Chinese Patients with EGFR Mutation-positive NSCLC: A Real-World Study

Back to course

Pdf Summary

This real-world study evaluates the efficacy of Furmonertinib as a first-line treatment for Chinese patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), focusing on locally advanced or metastatic cases. Conducted in a single center and spanning a cohort of 72 patients, the retrospective study observed patients who received Furmonertinib at 80 mg daily from August 2022 to March 2024. The key objectives included measuring progression-free survival (PFS) and assessing the objective response rate (ORR), overall survival (OS), and treatment safety.<br /><br />The study highlighted a median follow-up of 14.7 months, during which the ORR reached 77.8%, with the intracranial ORR even higher at 84.6%. The median PFS was found to be 19.9 months, while PFS for patients without brain metastases was not reached, and those with brain metastases presented a median PFS of 16.7 months.<br /><br />In terms of safety, adverse events were reported in 24 patients, with the most common including diarrhea, anemia, and liver injury. Severe adverse events (Grade 3 or higher) were observed in 5.6% of patients, suggesting Furmonertinib is a generally tolerable treatment option.<br /><br />Univariate and multivariate analyses indicated that factors such as age, smoking status, liver metastases, and ECOG scores are associated with prognosis. Notably, multivariate analysis suggested younger patients might experience prolonged PFS, although statistical significance was marginal.<br /><br />Overall, the study supports Furmonertinib as an effective and manageable first-line therapy option for EGFR mutation-positive NSCLC patients in a real-world setting, though further data and evaluations are necessary to strengthen these findings.

Asset Subtitle

Ning Yan

Meta Tag

Speaker Ning Yan

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

Furmonertinib

EGFR mutation

NSCLC

first-line treatment

progression-free survival

objective response rate

adverse events

real-world study

Chinese patients

brain metastases